Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 14Head & Neck 3Gynecologic 3Genitourinary 3Gastrointestinal 3Breast 3Dermatologic 2

Conditions

Melanoma 300Carcinoma, Non-Small-Cell Lung 80Squamous Cell Carcinoma of Head and Neck 59Carcinoma, Renal Cell 58Neoplasms 40Neoplasm Metastasis 36Colorectal Neoplasms 36Stomach Neoplasms 29Carcinoma, Merkel Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 28Carcinoma, Transitional Cell 27Uterine Cervical Neoplasms 24Skin Neoplasms 24Head and Neck Neoplasms 24Lung Neoplasms 22Breast Neoplasms 21Carcinoma, Hepatocellular 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 18Pancreatic Neoplasms 16Uveal Melanoma 14Small Cell Lung Carcinoma 14Sarcoma 14Urinary Bladder Neoplasms 12Lymphoma 11Kidney Neoplasms 11Endometrial Neoplasms 11Brain Neoplasms 11Prostatic Neoplasms 10

Interventions

pembrolizumab 2vandetanib 1trametinib 1tislelizumab 1spartalizumab 1ribociclib 1naporafenib 1motesanib diphosphate 1milademetan 1fludarabine phosphate 1Specimen Handling 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Interleukin-13 1IFL protocol 1Gemcitabine 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × pembrolizumab × Dermatologic × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04452214 2023-07-14

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Cantargia AB

Phase 1 Completed
19 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡